October 11, 2012

April, 4, 2011



Multifunctional Radical Quenchers for the Treatment of Mitochondrial Dysfunction

Gerard Rosse*

Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States Adjunct Associate Professor, Department of Pharmacology and Physiology, Drexel University, College of Medicine, New College Building, 245 N. 15th Street, Philadelphia, Pennsylvania 19102

Title:

Patent/Patent Application Number:

Priority Application:

Inventors:

Assignee Company:

Disease Area:

Summary:

Important Compound Classes:

Key Structures:

Multifunctional Radical Quenchers for the Treatment of Mitochondrial Dysfunction

WO 2012138713 A2 Publication Date:

US 2011-471346P Priority Date: Hecht, S.; Khdour, O.; Chowdhury, S. R.; Talukder, P.

Arizona State University, United States

Mitochondrial disorders, Mechanism of Action:

Quench reactive oxygen species (ROS), augment ATP production neurodegenerative disease

This invention provides a series of compounds as multifunctional radical quenchers. This class of compounds is useful for the treatment or suppression of diseases associated with decreased mitochondrial function resulting in ATP production and/or oxidative stress. In addition, such compounds may mitigate the effect of aging.

1. Davis, R. E.; Williams, M. Mitochondrial function and dysfunction: an update. J. Pharm. Exp. Ther. 2012, 342

12

Recent Review Articles: (3), 598-607.

2. Soustiel, J. F.; Zaaroor, M. Mitochondrial targeting for development of novel drug strategies in brain injury. Cent. Nerv. Syst. Agents Med. Chem. 2012, 12 (2), 131–145.

CPD-13

Received: November 15, 2012 Published: November 30, 2012



Biological Assays (Description):

3. Mathew, B. B.; Tiwari, A.; Jatawa, S. K. Free radicals and antioxidants: a review. *J. Pharm. Res.* **2012**, 4 (12), 4340–4343.

Compounds have been evaluated in a series of in vitro assays:

- Lipid peroxidation assay
- Mitochondrial membrane potential assay
- Trypan Blue Cell viability assay ok
- Cell viability assay ok

NADH oxidase inhibition assay

Pharmacological Data:

NADH oxidase inhibition assay

	NADH oxidase (complex I, III, IV) activity (%)	
	5 μΜ	1 μΜ
CPD-1	20.7 +/- 2.2	29.7 +/- 3.8
CPD-2	12 +/- 0.8	20.1 +/- 1.4
CPD-3	76.7 +/- 6.9	92.9 +/- 10.9
CPD-4	12.7 +/- 1.7	17.1 +/- 1
CPD-5	44.5 +/- 3.6	74.5 +/- 6.9

Lipid peroxidation suppression assay

	Scavenging activity (%)	
	5 μΜ	1 μΜ
Untreated	100	100
control		
Treated	0	0
control		
CPD-1	0	0
CPD-2	13 +/- 4.2	7 +/- 2.8
CPD-3	9.6 +/- 2.8	14 +/- 4.1
CPD-4	94 +/- 0.2	18 +/- 2.2
CPD-5	2.2 +/- 2.3	11 +/- 1.8
CPD-6	0	0
CPD-7	0	0
CPD-8	20 +/- 3.4	10 +/- 4.3
CPD-9	0	0
CPD-10	0	0
CPD-11	15 +/- 3.3	7 +/- 2.3
CPD-12	0	0
CPD-13	0	0

Claims 8, 12–16: Use of compounds for the treatment of Friedreich's ataxia, Kearns–Sayre syndrome, Huntingtons's disease, Alzheimer's disease, Parkinson's disease

Corresponding Author

*E-mail: grosse@dartneuroscience.com.

AUTHOR INFORMATION

Notes

Claims:

The author declares no competing financial interest.